Brainstorm Cell Therapeutics, Inc. (BCLI) saw downtrend of -7.87% in the recent trading with $0.36 being its most recent. The current price level -83.69% lower than the highest price of $2.21 marked by the stock while trading over the past 52-weeks, whereas it is 168.96% higher than the lowest price of $0.13 the company dropped to over past 52-weeks. The latest news story on BCLI appeared in (PR Newswire) under the title “BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Squeezing the time span to 30 day period shows us the stock is currently trading -35.65% below one month high and is +9.21% above of the lowest during that time. Looking into the simple moving average, Brainstorm Cell Therapeutics, Inc. (BCLI)’s stock stands at a SMA-50 of $0.4706 while that of 5-day is reading $0.3787.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and BCLI’s SMA-200 as of now is $0.3900.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Brainstorm Cell Therapeutics, Inc. Earnings – What Happened With BCLI
Coming around sales and income figures on BCLI Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Brainstorm Cell Therapeutics, Inc. (BCLI) last released financial results for the quarter that ended 3/31/2024, posting a surprise factor of 28.60% for net revenue.
BCLI – Brainstorm Cell Therapeutics, Inc. Stock Earnings Estimates
The perspective of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.07 for stock’s EPS in the current quarter. 1 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.05.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 70.08 million. BCLI does have institutional investors; and they hold 5.77% of the stock.
Brainstorm Cell Therapeutics, Inc. – Insider Activity and Holdings
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Technical Analysis of Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Brainstorm Cell Therapeutics, Inc. (BCLI), we notice that the stock’s 20-day average volume is at 728,865 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 683,190 shares. And to end, BCLI’s 100-day average volume is 866,939 shares with 50% of the long-term indicators pointing towards Sell for the stock.
